McAndrews Secures $32 Million Damages Award for Piramal Healthcare


On October 20, the United States District Court for the District of Delaware awarded Piramal Healthcare and their marketing partner, Slate Run Pharmaceuticals, $28.7 million in lost profit damages, plus $4 million in prejudgment interest. The court determined that Piramal and Slate Run would have earned those profits from sales of their generic cinacalcet tablets had they not been wrongfully enjoined between April 2019 and April 2020. McAndrews previously won a trial victory of noninfringement for Piramal in July 2019 and Federal Circuit affirmance of that decision in April 2020. Piramal developed and obtained FDA approval of its cinacalcet tablets – a generic version of Amgen’s Sensipar® tablets – for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis.

Piramal is represented by Aaron Barkoff, Alejandro Menchaca, and Ben Mahon.

Read the full opinion here.